A deep dive into the exciting advancements in nucleic acid therapeutics and how they're shaping the future of medicine.
Itinerary:
6:00 PM - 6:05 PM
Introduction to the event
Alex Samoshkin, Deputy Head, Office for Translational Research and Maxwell Centre, University of Cambridge
6:05 PM - 6:15 PM
Nucleic Acid Medicines like you```ve never seen before!
Mark Edbrooke, Independent Scientific Consultant, Cambridge-London. Mark specialises in oligonucleotide therapeutics and macromolecule delivery. He worked for 25 years in GlaxoSmithKline (GSK) before joining AstraZeneca, working with Sirna Therapeutics (therapeutic siRNA), Ionis (therapeutic antisense), Regulus (microRNA), and Moderna (modified RNA). He now consults for numerous UK- and European-based universities, UK- and US-based investment companies, and small biotechs across the globe, including being Head of Translational Research at Argonaute RNA Ltd., and on the Scientific Advisory Board for Deep Genomics.
6:15 PM - 6:35 PM
Discovery, translation and early development of oligonucleotide therapeutics
Dan Swerdlow, Senior director, Discovery Medicine, GSK, Stevenage. Dan qualified in medicine from the MD PhD programme at UCL in 2013, during which he completed a PhD in genetic epidemiology.
6:35 PM - 6:55 PM
mRNA encoding Myc&CyclinT1 improves cardiac function after myocardial injury
Catherine Wilson, Department of Pharmacology, University of Cambridge Catherine is an Associate Professor in the Department of Pharmacology and a Fellow, Wolfson College.
6:55 PM - 7:15 PM
NATA: new opportunities for technical development and translation
Peter Oliver, Nucleic Acid Therapy Accelerator (NATA), University of Oxford. Pete comes to NATA with over 25 years’ experience in cell and molecular biology.
7:15 PM - 8:00 PM
Buffet and networking
